Combined Forces Drive BTTC
The Brain Tumor Trials Collaborative (BTTC) was created in 2003 - a combined effort of many professionals, entities and organizations to help those suffering from brain tumors. The National Cancer Institute's (NCI) Center for Cancer Research serves as the lead institution and provides the administrative infrastructure, clinical database and oversight for the collaborative.
Several additional brain cancer-focused medical centers have since joined the BTTC. These institutions allow patients across a broad geographic range to participate in cutting-edge clinical trials and more rapidly determine the benefits of various therapies.
The mission of the BTTC is to develop and perform state-of-the-art clinical trials in a collaborative and collegial environment, advancing treatments for patients with brain tumors, merging good scientific method with concern for patient well-being and outcome.
Goals of the BTTC
- Provide patients access to innovative treatments through the BTTC Clinical Trials Network.
- Accelerate the pace of translating laboratory findings into hypothesis-based clinical trials.
- Perform state-of-the-art clinical trials emphasizing innovation and mandating meticulous attention to protocol compliance and data quality.
- Evaluate the impact of therapy by integrating measures of cancer response and patient outcomes.
Adding Immune-based Treatments to Standard Glioblastoma Therapy October 11, 2017
This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide) plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.
The BTTC newsletters include the latest information, accomplishments, and other useful updates.
BTTC Annual Meeting July, 2018
The inauguralMeeting was held in conjunction with the (BTTC) Annual Meeting at the National Institutes of Health (NIH). The meetings on June 11-12, 2018, were hosted by the Neuro-Oncology Branch at the Center for Cancer Research, National Cancer Institute, and was the largest BTTC meeting to date with over 100 attendees.
BTTC Annual Meeting June, 2017
The Brain Tumor Trials Collaborative held a productive meeting on March 31, 2017 at the National Institutes of Health (NIH). At the meeting, which included neuro-oncologists from 26 hospitals across the United States, BTTC members shared information about current and upcoming clinical trials.
Published BTTC Articles and Presentations
- A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients, Journal of Neuro-Oncology 2015
- Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102), ASCO 2015
- A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01, ASCO 2015
- Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma, Neuro-Oncology 2015
- BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation, ASCO 2013
- Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM), ASCO 2012